The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms

Abstract

In order to investigate the inhibitory effects of Endostar (rh-endostatin, YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the interaction mechanisms of combined therapy, the transplantation tumor models of A549 lung adenocarcinoma were established. When the largest diameter of tumor reached 1.0 cm, all nude mice were randomly divided into 4 groups: Endostar group, radiotherapy group, radiotherapy plus Endostar (combined treatment) group, and control group (n=6 in each group). The largest diameter and the vertical diameter of tumor were measured at different time points. At the 16th day, mice were executed, and the tumors were applied to analysis of rate of tumor cell apoptosis, and the expression levels of basic fibroblast growth factor (bFGF) mRNA were detected by reverse transcription-polymerase chain reaction (RT-PCR) and those of vascular endothelial growth factor (VEGF) by immunohistochemistry. The results demonstrated that the rate of tumor inhibition in combined treatment group was higher than that in other groups. And the rate of tumor cell apoptosis in combined treatment group was also higher than that in other groups. Meanwhile, the levels of bFGF mRNA and VEGF expression in combined treatment group were lower than those in other groups. It was concluded that Endostar obviously enhanced the curative effectiveness of radiotherapy on lung adenocarcinoma A549 in mice. The underlying mechanisms may involve the down-regulation of bFGF mRNA and VEGF expression to inhibit angiogenesis by Endostar and the cooperative effect of Endostar and radiotherapy to synergistically promote tumor cell apoptosis. And Endostar inhibits angiogenesis by down-regulating the expression of bFGF mRNA and VEGF.

Keywords

lung neoplasms / human lung adenocarcinoma cell line A549 / xenografted tumor / recombinant human Endostatin / radiotherapy

References

[1] TyldesleyS., BoydC., SchiclzeK., et al.. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys, 2001, 49(4): 973-985

[2] MizukamiY., KohgoY., ChungD.C., et al.. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res, 2007, 13(19): 5670-5674

[3] KoukourakisM.I., GiatromanolakiA., SivridisE., et al.. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res, 2001, 21(6B): 4301-4309

[4] ZicheM., ParentiA., LeddaF., et al.. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res, 1997, 80(6): 845-852

[5] OhnishiS.T., OhnishiT., NishinoK., et al.. Growth inhibition of cultured human liver carcinoma cells by Ki-energy (Life-energy): Scientific evidence for Ki-effects on cancer cells. Evid Based Complement Alternat Med, 2005, 2(3): 387-393

[6] O’ReillyM.S., BoehmT., ShingY. e. a1.. Endostatin: An endogenous inhibitor of angiogensis and tumor growth. Cell, 1997, 88(2): 277-285

[7] WangJ.W., SunY., LiuY.Y., et al.. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chinese), 2005, 8(4): 283-290

[8] LeeC.G., HeijnM., di TomasoE., et al.. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res, 2000, 60(19): 5565-5570

[9] JainR.K.. Determinants of tumor blood flow: a review. Cancer Res, 1988, 48(10): 2641-2658

[10] JainR.K.. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng, 1999, 1: 241-263

[11] JainR.K.. Normalizing tumor vasculature with anti-angiogenictherapy: a new paradigm for combination therapy. Nat Med, 2001, 7(9): 987-989

[12] BowersG., ReardonD., HewittT., et al.. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene, 2001, 20(11): 1388-1397

[13] BriegerJ., SchroederP., GosepathJ., et al.. Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cells after irradiation and increase resistance to subsequent irradiation. Int J Mol Med, 2005, 16(1): 159-164

[14] GridleyD.S., BonnetR.B., BushD.A., et al.. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2004, 60(3): 759-766

[15] ReisR.C., SchuppanD., BarretoA.C., et al.. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. Biochem Biophys Res Commun, 2005, 333(3): 976-983

[16] ChungY.L., JianJ.J., ChengS.H., et al.. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res, 2006, 12(9): 2706-2715

[17] LingY., YangY., LuN., et al.. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 2007, 361(1): 79-84

[18] ZacharyI.. Vascular endothelial growth factor. Int J Biochem cell Biol, 1998, 30(11): 1169-1174

[19] MauceriH.J., HannaN.N., BeckettM.A., et al.. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature, 1998, 394(6690): 287-291

[20] TeicherB.A., HoldenS. A., AraG., et al.. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer, 1995, 61(5): 732-737